)
Jasper Therapeutics (JSPR) investor relations material
Jasper Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Special meeting set for Nov. 13, 2026; seeks Nasdaq approval for conversion of merger and PIPE preferred stock, ratification of Patrick Crutcher’s board appointment, and authority to adjourn if needed.
Kira acquisition closed July 16, 2026; a private placement closed July 20, 2026, raising $132 million through preferred stock convertible into common shares.
Board recommends FOR all four proposals; merger itself and the merger agreement are not being submitted for a stockholder vote.
Voting matters and shareholder proposals
Merger conversion proposal seeks Nasdaq Rule 5635(a) and (b) approval for common shares issuable on conversion of merger preferred stock and exercise of Kira options; PIPE proposal seeks Rule 5635(d) approval for PIPE preferred conversion.
Each proposal requires a majority of shares present or represented by proxy and entitled to vote; abstentions count against, while broker non-votes do not affect the outcomes.
Proposal 3 asks stockholders to ratify Patrick Crutcher’s appointment; Proposal 4 would authorize adjournment to solicit more votes if support for Proposals 1–3 is insufficient.
Directors and officers agreed to vote shares representing ~1% of pre-transaction common stock FOR Proposals 1–3; the Board recommends FOR each proposal.
Board of directors and corporate governance
Patrick Crutcher joined the Board as a Class I director on July 16, 2026, as Kira’s designee; he also joined the Audit, Compensation, and Nominating and Corporate Governance committees.
Crutcher has 15+ years of biotechnology leadership and business development experience; his appointment remains effective if stockholders do not ratify it, though the Board will consider the vote in evaluating continued service.
Crutcher’s non-employee director terms include $40,000 annual cash compensation and a 15,000-share option grant, with 25% vesting after one year and the remainder monthly over 48 months, subject to continued service.
- A 284.0M-share resale shelf amid conversion, dilution and going-concern risks.JSPR
Registration filing - Conversion votes could unlock major dilution while addressing Nasdaq listing risks.JSPR
Proxy filing - Merger creates a well-funded, multi-asset immunology pipeline with major clinical milestones ahead.JSPR
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote on a reverse stock split, share increase, and adjournment to support compliance and growth.JSPR
Proxy filing - Shareholders will vote virtually on a reverse split and share increase to support compliance and growth.JSPR
Proxy filing - Net loss narrowed, but going concern risk persists despite Kira acquisition and $132M financing.JSPR
Q2 2026 - Briquilimab shows high efficacy and durability in urticaria, with pivotal Beacon data expected soon.JSPR
Stifel 2024 Healthcare Conference - Briquilimab shows strong efficacy and safety in mast cell diseases, with pivotal trials ahead.JSPR
Jefferies Global Healthcare Conference 2025 - Misdiagnosis explained BEACON anomalies; briquilimab showed efficacy and safety in asthma.JSPR
Study Result
Next Jasper Therapeutics earnings date
Next Jasper Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage
)